Evaluation of Antiphospholipid Antibodies and Activated Partial Thromboplastin Time in Women with Adverse Outcome of Pregnancy

evaluation of antiphospholipid antibodies and activated partial thromboplastin time in women with adverse outcome of pregnancy

adverse outcome of pregnancy is a potentially dangerous complication of conception and affects 15-20% of pregnancies. according to recent studies increased level of blood antiphospholipids antibodies, if accompanied by predisposing factors, can be an adverse event in human pregnancy. the aim of the present study was to compare the maternal serum levels of anticardiolipin and antiphosphatidyl se...

Laboratory Methodologic Approach in Prolonged Activated Partial Thromboplastin Time Test

The pathological activated partial thromboplastin time test is a data that we can find in all clinical laboratories routinely. The hemato-coagulative clinical case here reported aims to point out how the laboratory can provide a correct diagnosis by methodological rational setting and, consequently, carry out an appropriate therapy, or reassure the patient that the pathological data will not ca...

evaluation of fat atrophy in patients with dermis fat graft of orbit by ct-scan

چکیده ندارد.

Comparison of Antiphospholipid Antibodies between Preeclamptsia and Normal Pregnant Women

Antiphospholipid antibodies (APLA) may be detected in normal pregnancies and also may cause thrombosis, recurrent fetal loss, placental infarction and preeclampsia. In the present study the possible differences in APLA titer between healthy pregnant women and preeclampsia cases without history of thrombosis was examined. The APLA titer in 50 healthy pregnant women with 50 preeclampsia cases wit...

Adverse Pregnancy Outcome in Antiphospholipid Antibodies Syndrome: Pathogenic Mechanisms and Clinical Management

Leader How to treat women with antiphospholipid antibodies in pregnancy?

The persistent presence in plasma of medium to high levels of IgG and/or IgM class anticardiolipin antibodies (aCL) and/or the lupus anticoagulant (LAC) is associated with both “recurrent pregnancy loss” and venous and arterial thrombosis. This clinicoserological entity, first described in the early eighties in patients with systemic lupus erythematosus was termed the antiphospholipid syndrome ...